Listing 5.06 in 2026: How Social Security Decides Crohn's Disease and Ulcerative Colitis Claims Under 5.06A and 5.06B, Why the Two Obstructions Rule and the BMI 17.5 Threshold Decide Most Cases, and What Wins When the Listing Falls Short

Published June 19, 2026 by Anthony Albert, Benefits Research Director, Disability Exchange. Sources cited from SSA Blue Book Listing 5.06, 20 CFR 404.1525, POMS DI 24580.005, POMS DI 22505 series, and SSR 23-2p on consultative examinations.

Inflammatory bowel disease is one of the most under-approved conditions at the initial level. The denial rate at DDS sits well above 60 percent for first-time Crohn's and ulcerative colitis claims, even when the patient has been hospitalized multiple times, lost 30 pounds, and is on biologics that aren't working. The reason almost always traces back to Listing 5.06. The criteria are tight, the documentation requirements are specific, and most treating gastroenterologists don't write notes in the language SSA uses to score the listing. That's a fixable problem, but it requires you to know exactly what the listing demands.

This is the deep dive. We'll walk through Listing 5.06's two paths in detail, why the BMI 17.5 threshold under 5.06B trips up so many cases, what the two-obstructions rule under 5.06A actually requires, the biologic and steroid treatment records that move the needle, and how to win the case at residual functional capacity when the listing isn't met. We'll cover Crohn's, ulcerative colitis, indeterminate colitis, microscopic colitis, and a worked example of a real claim path.

Where Listing 5.06 sits in the rules

Listing 5.06 is found in Section 5.00 of the adult Listing of Impairments, codified at 20 CFR Part 404, Subpart P, Appendix 1. Section 5.00 covers digestive disorders generally. Listing 5.06 specifically covers inflammatory bowel disease (IBD) documented by endoscopy, biopsy, appropriate medically acceptable imaging, or operative findings. The listing has two independent paths to disability, labeled A and B. You only have to meet one.

The conditions that fall under 5.06 include Crohn's disease (regional enteritis), ulcerative colitis, indeterminate colitis when the pathology can't distinguish Crohn's from UC, and several rarer IBD variants. Microscopic colitis (lymphocytic colitis, collagenous colitis) usually gets evaluated under 5.08 weight loss rather than 5.06 because the inflammation pattern is different and the listing's obstruction and weight criteria don't fit as cleanly.

The 5.00E preamble lays out documentation requirements. SSA wants the diagnosis confirmed by endoscopic biopsy, imaging (CT enterography, MR enterography, capsule endoscopy), or surgical findings. Self-reported diarrhea and abdominal pain alone don't establish IBD. You need the pathology report or the imaging study.

The 5.06A path: two obstructions in six months

Listing 5.06A grants disability when there's been an obstruction of stenotic areas in the small intestine or colon, with proximal dilation, confirmed by appropriate medically acceptable imaging or in surgery, requiring hospitalization for intestinal decompression or for surgery, and occurring on at least two occasions at least 60 days apart within a consecutive 6-month period.

Let's unpack that sentence because every word is doing work.

• Obstruction of stenotic areas. The blockage has to occur at a stricture or stenosis. Adhesive obstructions from prior surgery don't count under 5.06A unless they also involve IBD-related stenosis. The radiology report or operative note has to identify the stenotic location, usually in the terminal ileum, ileocecal valve, or rectosigmoid colon.
• Proximal dilation. The CT or MR has to show the bowel proximal to the stricture is dilated. This is what distinguishes a true obstruction from a chronic stricture without functional obstruction. Without proximal dilation, the imaging doesn't satisfy 5.06A even if the patient is symptomatic.
• Imaging confirmation or surgical findings. CT enterography is the standard. MR enterography is acceptable. Plain X-ray with contrast can work. Surgical findings count if there's an operative report describing the obstruction.
• Hospitalization required. The patient has to have been admitted to the hospital for intestinal decompression (NG tube placement, IV fluids, bowel rest) or for surgery. Emergency department visits that don't lead to admission don't count.
• Two occasions at least 60 days apart. Two separate hospitalizations. The 60-day spacing is critical. Two hospitalizations 30 days apart for the same obstructive episode don't satisfy 5.06A. The first must clearly resolve, and the second must be a new event.
• Within a consecutive 6-month period. The two hospitalizations have to fall within the same 6-month window. A Crohn's patient hospitalized in January and then again in November of the same year doesn't meet 5.06A on those events alone.

The 5.06A path is best suited to Crohn's patients with stricturing disease, particularly the B2 phenotype of the Montreal classification. Ulcerative colitis usually doesn't produce the same obstructive pattern because UC is mucosal rather than transmural. UC patients are more likely to meet 5.06B.

The 5.06B path: six findings in six months with BMI 17.5

Listing 5.06B grants disability when, on at least two evaluations at least 60 days apart within a consecutive 6-month period, the patient has two of six listed findings. The six findings are:

1. Anemia with hemoglobin of less than 10.0 g/dL.
2. Serum albumin of 3.0 g/dL or less.
3. Clinically documented tender abdominal mass palpable on physical examination with abdominal pain or cramping that is not completely controlled by prescribed narcotic medication.
4. Perineal disease with a draining abscess or fistula, with pain that is not completely controlled by prescribed narcotic medication.
5. Involuntary weight loss of at least 10 percent from baseline, as computed in pounds, kilograms, or BMI.
6. Need for supplemental daily enteral nutrition via a gastrostomy or daily parenteral nutrition via a central venous catheter.

Two of these on each of two evaluations spaced at least 60 days apart, within a single 6-month window. That's the 5.06B test.

The BMI 17.5 threshold gets cited in claimant guides because BMI below 17.5 used to be one of the listed findings under earlier versions of the regulation. The current 5.06B uses involuntary weight loss of at least 10 percent from baseline instead, with BMI as an acceptable computation method. A 5 foot 7 inch patient who drops from 150 pounds to 135 pounds has lost exactly 10 percent and meets that finding. If the same patient's baseline was 160 pounds, dropping to 144 hits the 10 percent threshold.

The lab findings matter most. Hemoglobin under 10 and albumin at or below 3.0 are objective, easy to document, and often persistent in active IBD. Two CBCs and two CMPs spaced 60 days apart can do the heavy lifting for 5.06B if the patient also has documented weight loss, an abdominal mass, or perineal disease.

The pain control language in 5.06B

Two of the six findings include the phrase "not completely controlled by prescribed narcotic medication." That language is doing more work than people realize. SSA wants the treating record to document that the patient is on prescribed opioids for IBD pain and that those opioids are not fully controlling the pain. This is a real evidentiary requirement, not a casual statement.

Treating gastroenterologists are increasingly reluctant to prescribe long-term opioids for IBD because of the opioid epidemic and because opioids can worsen the underlying disease (narcotic bowel syndrome, ileus, masking of obstruction symptoms). That clinical caution creates a documentation gap. Patients with severe IBD pain may not be on prescribed opioids, which can knock them out of two of the six 5.06B findings.

The workaround is straightforward. If the patient is on prescribed opioids, the treatment notes should document inadequate pain control. If the patient is not on prescribed opioids, the treating gastroenterologist should explain in writing why opioids are contraindicated, what alternative pain medications have been tried (acetaminophen, tramadol, gabapentin, antispasmodics), and that the pain remains uncontrolled despite those efforts. SSA will weigh the medical reasoning rather than rigidly applying the "narcotic" language when the record explains the clinical decision.

Biologic therapy and treatment failure documentation

The treatment record for IBD has changed dramatically since the listing was last revised. In 2026, the standard of care for moderate to severe Crohn's and ulcerative colitis includes biologics like infliximab (Remicade), adalimumab (Humira), vedolizumab (Entyvio), ustekinumab (Stelara), risankizumab (Skyrizi), and mirikizumab (Omvoh). JAK inhibitors like upadacitinib (Rinvoq) and tofacitinib (Xeljanz) are also in the rotation. The fact that a patient has failed or is failing biologics matters enormously to the residual functional capacity analysis even when the listing isn't met.

SSA expects treating gastroenterologists to document the full treatment history. Aminosalicylates (mesalamine, sulfasalazine) tried and failed. Steroids (prednisone, budesonide) tried, often producing dependency. Immunomodulators (azathioprine, 6-mercaptopurine, methotrexate) tried and inadequate. Then biologics started, often cycled through two or three before finding one that works, with each switch documented as primary nonresponse or secondary loss of response.

Treatment failure documentation translates directly into a stronger claim. A Crohn's patient who has failed three biologics, has elevated calprotectin despite treatment, and continues to have active disease on endoscopy is a much stronger residual case than a patient whose chart simply says "Crohn's disease, ongoing." The active disease on objective testing is what carries the weight.

When the listing isn't met: residual functional capacity

Plenty of IBD claims don't meet 5.06A or 5.06B. The patient hasn't been hospitalized twice in six months. The labs are stable. The weight loss didn't reach 10 percent. But the disease is still preventing work. These cases have to win at Steps 4 and 5 of the sequential evaluation through the residual functional capacity analysis.

The IBD residual case is built on specific functional limitations tied to disease symptoms.

• Bathroom frequency. Active Crohn's or UC can produce 8 to 15 bowel movements per day. The treating record has to document the frequency, the urgency, and the impact on the ability to stay at a workstation. SSA recognizes that no competitive employer tolerates an employee who has to leave the work area unpredictably multiple times per hour.
• Fatigue. IBD-related fatigue from anemia, malnutrition, and active inflammation is real and measurable. Hemoglobin trends, ferritin levels, and B12 status all support the fatigue claim. Sleep disruption from nighttime bowel movements compounds the problem.
• Joint involvement. About 20 percent of IBD patients develop extraintestinal joint manifestations including peripheral arthritis, axial arthritis, and ankylosing spondylitis-like patterns. Joint pain limits sitting tolerance, standing tolerance, and lifting capacity.
• Cognitive impairment. Active IBD with chronic anemia and protein malnutrition produces measurable cognitive slowing. Treatment with steroids adds mood symptoms and concentration deficits.
• Pain. Chronic abdominal pain, perianal pain, and joint pain are common. Pain limits attention, persistence, and pace.

The medical source statement from the treating gastroenterologist should translate these symptoms into specific work limitations. How long can the patient sit before needing to use the bathroom? How long can the patient stand? How many unscheduled breaks per day? How many missed workdays per month? Specific, quantified limits are what move the residual case forward.

The worked example

State-by-state notes

IBD claims are processed at the state DDS level. Allowance rates at initial determination vary widely. Some states have specialty medical consultants who handle gastrointestinal cases, which tends to speed up the file and improve approval rates. If you're filing in a backlog-heavy state, consider whether your file is strong enough to pursue an on-the-record decision at the ALJ level. See state-specific guides for California, Texas, Florida, New York, and Illinois.

Related deep dives

• Social Security Disability for Crohn's disease overview
• Listing 5.05 chronic liver disease deep dive
• Listing 14.09 inflammatory arthritis deep dive
• Medical source statement HA-1151 and HA-1152
• SSR 16-3p subjective symptom evaluation

Frequently asked questions